K
Kathryn J Howells
Researcher at AstraZeneca
Publications - 6
Citations - 177
Kathryn J Howells is an academic researcher from AstraZeneca. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 2, co-authored 3 publications receiving 104 citations.
Papers
More filters
Journal ArticleDOI
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers
Monique B. Nilsson,Huiying Sun,Lixia Diao,Pan Tong,Diane Liu,Lerong Li,Youhong Fan,Alissa Poteete,Seung Oe Lim,Kathryn J Howells,Vincent Haddad,Daniel R. Gomez,Hai T. Tran,Guillermo N. Armaiz Pena,Lecia V. Sequist,James Chih-Hsin Yang,Jing Wang,Edward S. Kim,Roy S. Herbst,J. Jack Lee,Waun Ki Hong,Ignacio I. Wistuba,Mien Chie Hung,Anil K. Sood,John V. Heymach +24 more
TL;DR: Evidence is provided that chronic stress hormones promote EGFR TKI resistance via β2-AR signaling by an LKB1/CREB (cyclic adenosine 3′,5′-monophosphate response element–binding protein)/IL-6–dependent mechanism and suggest that combinations of β-blockers with EG FR TKIs merit further investigation as a strategy to abrogate resistance.
Journal ArticleDOI
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
Tina Cascone,Li Xu,Heather Lin,Wenbin Liu,Hai T. Tran,Yuan Liu,Kathryn J Howells,Vincent Haddad,Emer O. Hanrahan,Monique B. Nilsson,Maria Angelica Cortez,Uma Giri,Humam Kadara,Humam Kadara,Babita Saigal,Yun-Yong Park,Weiyi Peng,Ju Seog Lee,Anderson J. Ryan,Juliane M. Juergensmeier,Roy S. Herbst,Jing Wang,Robert R. Langley,Ignacio I. Wistuba,J. Jack Lee,John V. Heymach +25 more
TL;DR: HGF/c-MET pathway mediates VEGFR inhibitor resistance and vascular remodeling in NSCLC and in patients with cancer receiving VEGfr TKIs, high pretreatment HGF plasma levels correlated with poorer survival.
Journal ArticleDOI
BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).
Jonathan E. Rosenberg,Se Hoon Park,Tuoc Dao,Daniel Castellano,Jian-Ri Li,Som D. Mukherjee,Kathryn J Howells,Hannah Dry,Mark C. Lanasa,Ross Stewart,Dean F. Bajorin +10 more
TL;DR: The results of pre-planned secondary analyses suggest a potential role for PARP inhibition in UC pts harboring HRRm, and the primary endpoint was progression-free survival (PFS) by RECIST v1.1 in the intention-to-treat (ITT) population.
Proceedings ArticleDOI
O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial
Bradley J. Monk,Takafumi Toita,Xiaohua Wu,Juan Carlos Limón,Qi Zhou,Rafal Tarnawski,Masaki Mandai,Ronnie Shapira-Frommer,Umesh Mahantshetty,Maria Del Pilar Estevez-Diz,Francisco Ramirez Godinez,Szilvia Varga,Manuel Humberto Leiva Gálvez,Jung-Yun Lee,Yu. M. Kreynina,Kathryn J Howells,Sophie Wildsmith,Hannah Dry,Ana Tablante Nunes,Jyoti Mayadev +19 more
TL;DR: The first global Phase 3 study evaluating immune checkpoint inhibition (durvalumab) versus placebo in combination with and following chemoradiotherapy (CRT) in locally-advanced cervical cancer (LACC) was presented in this article .
Journal ArticleDOI
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Jonathan E. Rosenberg,Se Hoon Park,Vadim E. Kozlov,Tu Van Dao,Daniel Castellano,Jian-Ri Li,Som D. Mukherjee,Kathryn J Howells,Hannah Dry,Mark C. Lanasa,Ross Stewart,Dean F. Bajorin +11 more
TL;DR: Adding olaparib to durvalumab did not improve survival outcomes in an unselected mUC population, and the results of secondary analyses suggest a potential role for PARP inhibition in patients with UC harboring HRRm.